NervGen Pharma

NervGen Pharma is a pharmaceutical company dedicated to creating solutions for the treatment of nerve damage and neurodegenerative diseases. The company's lead compound, NVG-291, is at the forefront in treating spinal cord injuries and multiple sclerosis. NervGen plans to initiate a Phase 1 clinical trial in healthy subjects in early 2020, with an expansion cohort of spinal cord injury patients planned for the second half of 2020. Additionally, the company intends to commence a Phase 2 multiple sclerosis clinical trial in early 2021.